Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 11/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.61 |
| ▸ | HTR1A | P08908 | 2/20 | 0.61 |
| ▸ | MLNR | O43193 | 1/20 | 0.61 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | DRD2 | P14416 | 1/20 | 0.61 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.61 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.61 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.61 |
| ▸ | HTR2C | P28335 | 1/20 | 0.61 |
| ▸ | MC4R | P32245 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3336 | 1.00 | SLC6A2 (0.61) | SLC6A2SLC6A4SLC6A3HTR1AMLNR | |
| SCHEMBL4108375 | 0.91 | SLC6A2 (0.58) | SLC6A2SLC6A4SLC6A3HTR1AMLNR | |
| SCHEMBL3413 | 0.91 | SLC6A2 (0.58) | SLC6A2SLC6A4SLC6A3HTR1AMLNR | |
| SCHEMBL9725764 | 0.91 | SLC6A2 (0.58) | SLC6A2SLC6A4SLC6A3HTR1AMLNR | |
| SCHEMBL4106328 | 0.87 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3HTR1AMLNR | |
| SCHEMBL5869349 | 0.86 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3HTR1AMLNR | |
| SCHEMBL9744 | 0.85 | SLC6A4 (0.49) | SLC6A2SLC6A4SLC6A3HTR1AMLNR | |
| SCHEMBL1535379 | 0.84 | SLC6A2 (0.62) | SLC6A2SLC6A4SLC6A3HTR1AMLNR | |
| SCHEMBL4104256 | 0.84 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3HTR1AMLNR | |
| SCHEMBL3312531 | 0.83 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3HTR1AMLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100432069-C | 3-methylamino-1- (2-thienyl) -1-acetone and preparation and application thereof | BASF AG (DE) | 2008-11-12 | — | — | CN | claimed |
| EP-1587802-B1 | PRODUCTION AND USE OF 3-METHYLAMINO-1-(2-THIENYL)-1-PROPANONE | BASF AG (DE) | 2007-11-14 | — | — | EP | claimed |
| US-7259264-B2 | 3-methylamino-1-(2-thienyl)-1-propanone, production and use thereof | BASF AKTIENGESELLSCHAFT (DE) | 2007-08-21 | — | — | US | claimed |
| US-20060128791-A1 | 3-Methylamino-1-(2-thienyl)-1-propanone, production and use thereof | BASF AKTIENGESELLSCHAFT (DE) | 2006-06-15 | — | — | US | claimed |
| CN-1742003-A | 3-methylamino-1-(2-thienyl)-1-propanone, production and use thereof | BASF AG (DE) | 2006-03-01 | — | — | CN | claimed |
| US-8269023-B2 | Process for preparation of duloxetine hydrochloride | LUPIN LTD. (IN) | 2012-09-18 | — | — | US | disclosed |
| WO-2011077443-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF DULOXETINE HYDROCHLORIDE | BIOCON LIMITED (IN) | 2011-06-30 | — | — | WO | disclosed |
| EP-1857451-B1 | A process for the preparation of an intermediate useful for the asymmetric synthesis of (+)duloxetine | FIDIA FARMACEUTICI (IT) | 2010-07-21 | — | — | EP | disclosed |
| US-20100105925-A1 | NOVEL PROCESS FOR PREPARATION OF DULOXETINE HYDROCHLORIDE | LUPIN LIMITED (IN) | 2010-04-29 | — | — | US | disclosed |
| CN-100432069-C | 3-methylamino-1- (2-thienyl) -1-acetone and preparation and application thereof | BASF AG (DE) | 2008-11-12 | — | — | CN | disclosed |
| US-7435835-B2 | Method for producing enantiomer-pure aminoalcohols | BASF AG (DE) | 2008-10-14 | — | — | US | disclosed |
| EP-1857451-A1 | A process for the preparation of an intermediate useful for the asymmetric synthesis of (+)duloxetine | SOLMAG S.p.A. (IT) | 2007-11-21 | — | — | EP | disclosed |
| EP-1587802-B1 | PRODUCTION AND USE OF 3-METHYLAMINO-1-(2-THIENYL)-1-PROPANONE | BASF AG (DE) | 2007-11-14 | — | — | EP | disclosed |
| US-7259264-B2 | 3-methylamino-1-(2-thienyl)-1-propanone, production and use thereof | BASF AKTIENGESELLSCHAFT (DE) | 2007-08-21 | — | — | US | disclosed |
| US-20070128704-A1 | Method for producing enantiomer-pure aminoalcohols | BASF AKTIENGESELLSCHAFT (DE) | 2007-06-07 | — | — | US | disclosed |
| US-20060128791-A1 | 3-Methylamino-1-(2-thienyl)-1-propanone, production and use thereof | BASF AKTIENGESELLSCHAFT (DE) | 2006-06-15 | — | — | US | disclosed |
| CN-1742003-A | 3-methylamino-1-(2-thienyl)-1-propanone, production and use thereof | BASF AG (DE) | 2006-03-01 | — | — | CN | disclosed |
| EP-1587802-A1 | 3-METHYLAMINO-1-(2-THIENYL)-1-PROPANONE, PRODUCTION AND USE THEREOF | BASF AKTIENGESELLSCHAFT (DE) | 2005-10-26 | — | — | EP | disclosed |
| WO-2004065376-A1 | 3-METHYLAMINO-1-(2-THIENYL)-1-PROPANONE, PRODUCTION AND USE THEREOF | BASF AKTIENGESELLSCHAFT (DE) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070128704-A1 | Method for producing enantiomer-pure aminoalcohols | ADH1A, ADH1C, ADH5 | SLC6A2 2935/4885SLC6A4 2006/4885SLC6A3 3205/4885 |
| US-20100105925-A1 | NOVEL PROCESS FOR PREPARATION OF DULOXETINE HYDROCHLORIDE | MAOA, SLC6A3, PNMT | SLC6A2 19/4885SLC6A4 16/4885SLC6A3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.